Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study by Masciale, Valentina et al.
ORIGINAL RESEARCH
published: 18 December 2019
doi: 10.3389/fonc.2019.01394
Frontiers in Oncology | www.frontiersin.org 1 December 2019 | Volume 9 | Article 1394
Edited by:
Etienne Giroux Leprieur,
Hôpital Ambroise-Paré, France
Reviewed by:
Jessica Desiree Menis,
Istituto Oncologico Veneto
(IRCCS), Italy
Conor Steuer,
Emory University, United States
*Correspondence:
Beatrice Aramini
beatrice.aramini@unimore.it
†These authors share first authorship
‡These authors share last authorship
Specialty section:
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 12 August 2019
Accepted: 26 November 2019
Published: 18 December 2019
Citation:
Masciale V, Grisendi G, Banchelli F,
D’Amico R, Maiorana A, Sighinolfi P,
Stefani A, Morandi U, Dominici M and
Aramini B (2019) Isolation and
Identification of Cancer Stem-Like
Cells in Adenocarcinoma and
Squamous Cell Carcinoma of the
Lung: A Pilot Study.
Front. Oncol. 9:1394.
doi: 10.3389/fonc.2019.01394
Isolation and Identification of Cancer
Stem-Like Cells in Adenocarcinoma
and Squamous Cell Carcinoma of the
Lung: A Pilot Study
Valentina Masciale 1†, Giulia Grisendi 2,3†, Federico Banchelli 4, Roberto D’Amico 4,
Antonino Maiorana 5, Pamela Sighinolfi 5, Alessandro Stefani 1, Uliano Morandi 1,
Massimo Dominici 2‡ and Beatrice Aramini 1*‡
1Division of Thoracic Surgery, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and
Reggio Emilia, Modena, Italy, 2Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults,
University of Modena and Reggio Emilia, Modena, Italy, 3 Rigenerand SRL, Modena, Italy, 4Department of Medical and
Surgical Sciences for Children & Adults, Center of Medical Statistic, University of Modena and Reggio Emilia, Modena, Italy,
5Department of Medical and Surgical Sciences for Children & Adults, Institute of Pathology, University of Modena and Reggio
Emilia, Modena, Italy
Background: Lung cancer stem cells (CSCs) share many characteristics with normal
stem cells, such as self-renewal and multipotentiality. High expression of aldehyde
dehydrogenase (ALDH) has been detected in many tumors, particularly in the CSC
compartment, and it plays an important role in tumor proliferation, metastasis, and drug
resistance. CD44 is commonly used as a cell surface marker of cancer stem-like cells
in epithelial tumors. The aim of this study was to isolate and analyze cancer stem-like
cells from surgically removed specimens to compare lung adenocarcinoma (ADENO)
and squamous (SQUAMO) cell carcinoma.
Methods: The ALDEFLUOR assay was used to identify and sort ALDHhigh and
ALDHlow human lung cancer cells following tissue digestion. Fluorescence-activated
cell sorting analysis for CD44 was performed with tumor cells. Quantitative real-time
PCR was performed to assess the expression of SOX2 and NANOG as stemness
markers. ALDH1A1 expression was additionally determined by immunohistochemistry.
Anchorage-independent ALDHhigh cell growth was also evaluated. ALDHhigh ADENO and
SQUAMO cells were cultured to analyze spheroid formation.
Results: All specimens contained 0.5–12.5% ALDHhigh cells with 3.8–18.9%
CD44-positive cells. SOX2 and NANOG relative expression in ALDHhigh compared
to ALDHlow cells in ADENO and SQUAMO was analyzed and compared between
the histotypes. Immunohistochemistry confirmed the presence of ALDH1A1
in the sections. SOX2 and NANOG were expressed at higher levels in the
ALDHhigh subpopulation than in the ALDHlow subpopulation only in ADENO
cells, and the opposite result was seen in SQUAMO cells. In vitro functional
assays demonstrated that ALDHhigh cells exhibited migration capacity with
distinct behaviors between ALDHhigh spheres in ADENO vs. SQUAMO samples.
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Conclusions: Our results highlight the importance of a better characterization of cancer
stem-like cells in ADENO and SQUAMO histotypes. This may suggest new differential
approaches for prognostic and therapeutic purposes in patients with non-small-cell
lung cancer.
Keywords: cancer stem-like cells, non-small-cell lung cancer, lung adenocarcinoma, lung squamous cell
carcinoma, CSC marker, aldehyde dehydrogenase
BACKGROUND
Lung cancer is the most common cancer worldwide, accounting
for 1.8 million new cases and 1.6 million deaths in 2012; the
number of deaths worldwide is expected to grow to 3 million
by 2035 (1, 2). Non-small-cell lung cancer (NSCLC) accounts
for 85–90% of all lung cancers. The primary treatment is
surgery for early stages (stages I and II) and chemotherapy,
radiotherapy, and/or immunotherapy for advanced-stage disease
(3–6). Chemotherapy drugs cannot differentiate between tumor
cells and normal cells while functioning; the treatment-related
adverse effects are noticeably strong and therefore feared by
patients. It was not until the emergence of targeted therapy
based on molecular typing that the survival period of patients
with advanced NSCLC was improved to several years. Until
2013, immunotherapy was crowned as the first place scientific
breakthrough (7). The efficacy of immunotherapy for those
without targetable oncogene mutations was proven from second-
line treatment (8–12) to first-line treatment (13, 14). Through
long-term follow-up, immunotherapy has also shown that it has
the greatest potential long-term clinical benefit (15, 16), even
though the efficacy is not fully satisfactory (17–24). Indeed,
similar to targeted therapy, patients may eventually develop
resistance to immunotherapy (25, 26), and some may even suffer
hyperprogression after immunotherapy (27, 28). The problem
of resistance has not yet been studied; however, recent data
suggest that cancer stem cells (CSCs) with characteristics of self-
renewal may be resistant to these therapies (29). Understanding
the role of CSCs in lung cancer may be very important and
useful for identifying future targets. Indeed, the development
of methods for the isolation and characterization of CSCs
from primary tumors is a critical step in understanding the
processes that mediate chemoresistance and for the development
of therapeutic strategies to overcome this resistance, including
promising immunotherapy approaches (29–31). To date, cancer
cell lines have been the most frequently used tools to study
lung CSCs (15, 16, 32). The identification of a specific marker
for CSCs in the lung remains controversial (33, 34). Current
studies provide increasing evidence for the existence of CSCs
using several specific biomarkers (e.g., CD133, CD90, and CD44)
translated from studies of human hematological malignancies
(35–37) and solid tumors (38–47). In particular, aldehyde
dehydrogenase (ALDH) activity is an important functional
Abbreviations: NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer;
ALDH, aldehyde dehydrogenase; FACS, fluorescence-activated cell sorting; CSCs,
cancer stem cells; SSC, side scatter; FSC, forward scattered; ECM, extracellular
matrix; ADENO, adenocarcinoma; SQUAMO, squamous cell carcinoma.
marker of normal and malignant stem/progenitor cells (47–51).
In addition, CSCs possess high ALDH activity, especially for
the predominant ALDH isozymes, ALDH1A1, and ALDH1A3.
Cortes-Dericks et al. (51) showed that the flow cytometry-
based ALDEFLUOR assay could be used to select ALDHhigh
and ALDHlow populations to discriminate the cancer stem-like
cell population from non-cancer stem-like cells. An enrichment
of CSCs in the ALDHhigh population was also described in
NSCLC patients and cell lines (52). In addition, several key
regulators have been described as essential for the maintenance
of a progenitor cell state under both normal and cancerous
conditions (e.g., SOX2 and the homeobox protein NANOG) (53,
54). Following these investigations, the aim of the present study
was to identify cancer stem-like cells in primary human lung
cancer cells obtained from surgical specimens and to assess the
differences and similarities between adenocarcinoma (ADENO)
and squamous (SQUAMO) cell carcinoma using a combination
of ALDH and CD44.
METHODS
The identification of cancer stem-like cells and the assessment of
the differences and similarities between ADENO and SQUAMO
were carried out by performing real-time PCR (RT-PCR), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS)
assays, and sphere cultures.
Collection of Tumor Specimens
This study was approved by the Regional Ethical Committee of
Modena University Hospital and performed according to the
guidelines of the Helsinki Convention. Upon signed informed
consent, human lung cancer tissues were obtained from four
consecutive patients with ADENO and four consecutive patients
with SQUAMO who underwent major surgical lung resection
between October 2017 and January 2018 at the Division of
Thoracic Surgery of the University Hospital of Modena for
stage I, II, or IIIA NSCLC (8th TNM) (Table 1). The collection
of tumor tissues was carried out during surgery and was set
according to the availability of the pathologists involved in our
study. The excision of the tumor tissue was performed only
from the primary lung nodule. The microscopic features of the
cancer cells and immunohistochemistry were used to assess the
histological diagnosis.
Dissociation of Primary Tissues
Freshly obtained tumor tissues (within 1–2 h after surgical
removal) were washed in sterile Dulbecco’s phosphate-buffered
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TABLE 1 | Patients characteristics, cellular yield from each sample, viability, and aldehyde dehydrogenase (ALDH) expression determined by fluorescence-activated cell
sorting (FACS).
Adenocarcinoma
(n = 4)
Squamous cell
carcinoma
(n = 4)
All patients
(n = 8)
PATIENTS CHARACTERISTICS
Age (years) Mean ± SD 66.7 ± 9.4 73.7 ± 7.9 71 ± 8.5
Gender (male) n (%) 3 (75.0%) 3 (75.0%) 6 (75.0%)
Smoker (yes) n (%) 4 (100.0%) 4 (100.0%) 8 (100.0%)
Stage (8th TNM)
IA3 n (%) 1 (25.0%) 1 (25.0%) 2 (25.0%)
IIA n (%) 2 (50.0%) 0 (0.0%) 2 (25.0%)
IIB n (%) 1 (25.0%) 1 (25.0%) 2 (25.0%)
IIIA n (%) 0 (0.0%) 2 (50.0%) 2 (25.0%)
Neoadiuvant Chemotherapy n (%) 1 (25.0%) 0 (0.0%) 1 (12.5%)
SAMPLE CHARACTERISTICS
Weight (g) Mean ± SD 1.0 ± 0.9 1.0 ± 0.6 1.0 ± 0.7
Cellular yield (million cells/g) Mean ± SD 18.2 ± 8.6 20.4 ± 8.2 19.3 ± 7.9
FACS ANALYSIS
7-AAD negative Mean ± SD 94.3 ± 5.2% 90.5 ± 6.8% 92.4 ± 6.0%
ALDHhigh Mean ± SD 3.7 ± 5.9% 4.2 ± 3.9% 4.0 ± 4.6%
SD, standard deviation. 7-Amino-actinomycin D (7-AAD) negative cells are expressed as percentage of total number of sorted cells. ALDHhigh are expressed as percentage of 7-AAD
negative cells.
saline (PBS) (L1825-BC—Merck Millipore) and mechanically
minced into small pieces (2–4mm). Minced samples were
digested using a tumor dissociation kit in a disposable gentle
MACSTM C-Tube (Miltenyi) according to the manufacturer’s
instructions. Samples were digested for 60min at 37◦C in a gentle
MACS Octo dissociator and filtered through 70-µm sterile cell
strainers, centrifuged at 300×g for 5min, and resuspended in
a mixture of Dulbecco’s modified Eagle medium (DMEM) and
Ham’s F12 media (2:1) (Gibco) containing 50 IU/ml penicillin–
streptomycin and 4mM glutamine. Finally, viable cells were
counted using an optic phase contrast microscope.
ALDEFLUOR Assay
Single-cell suspensions of the primary tumor cells from the
surgical tumor specimens were diluted in ALDEFLUOR assay
buffer containing BODIPY-aminoacetaldehyde (STEMCELL
Technologies, Vancouver, BC). The assay was performed
according to the manufacturer’s protocol. Briefly, at least 5
million tumor cells were resuspended in ALDEFLUOR buffer (5
µl/106) and stained with ALDEFLUOR substrate. Immediately
after, 5 × 105 cells were transferred to a control tube containing
5 µl diethylaminobenzaldehyde, which is a specific inhibitor
of ALDH. Both control and test samples were incubated for
45min at 37◦C protected from light. Following incubation, the
cells were centrifuged at 300×g for 5min. The cell pellet was
resuspended in 1ml ALDEFLUOR assay buffer. Cell morphology
was evaluated using side scatter (SSC) and forward scatter (FSC).
Dead cells were excluded using 7-amino-actinomycinD (7-AAD)
staining. Cell sorting and ALDH analysis were performed using
a FACSAria III instrument (Becton Dickinson, Franklin Lakes,
NJ). The results were analyzed using fluorescence-activated cell
sorting (FACS) Diva software (Becton Dickinson). The gating
strategy included the ALDHhigh gate, which was set at least one
log apart from the ALDHlow gate. Sorted cells were promptly
lysed for gene expression analysis.
FACS Analyses
Primary tumor cell suspensions were stained with
allophycocyanin-conjugated anti-CD45 (Becton Dickinson)
and phycoerythrin-conjugated anti-CD44 (BioLegend, San
Diego, CA). An isotype control sample for each condition was
used to exclude the autofluorescence background. Dead cells
were excluded using 7-AAD staining. The gate was set based on
CD45-negative cells. Analyses were performed using a FACSAria
III instrument (Becton Dickinson). Data were analyzed using the
FACSDiva software.
RNA Isolation and Real-Time PCR
Total cellular RNA was extracted from ALDHhigh and ALDHlow
cells using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. Total RNA (500 ng) was reverse
transcribed using the RevertAidTM First-Strand Complementary
DNA (cDNA) Synthesis Kit (Thermo Scientific). Following
cDNA synthesis, RT-PCR was performed in triplicate for each
sample using FAST SYBR
TM
Green detection chemistry (Applied
Biosystems) on Step One instrument. Human SOX2, NANOG,
and GAPDH were amplified using gene-specific primers
(GAPDH: forward primer 5′-ACATCGCTCAGACACCATG-3′,
reverse primer 5′TGTAGTTGAGGTCAATGAAGGG-3′; SOX2:
forward primer 5′-GGAAACTTTTGTCGGAGACG-3′, reverse
primer 5′-GCAGCGTGTACTTATCCTTC-3′; NANOG: forward
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primer 5′AGAAATACCTCAGCCTCCAG-3′, reverse primer 5′-
CGTCACACCATTGCTATTCTT-3′). The cycling parameters
consisted of denaturation at 95◦C for 10min; and 40 cycles of 15 s
at 94◦C, 30 s at 60◦C, and 1min at 72◦C; followed by a continuous
melting curve.
Immunohistochemistry
Slides were deparaffinized with xylene, rehydrated in a graded
alcohol series, and washed in PBS twice for 5min each. The
sections were heated in 10mM sodium citrate buffer, pH
6.0, for 15min in a 95◦C water bath for antigen retrieval.
PBS washes (5min each) were performed until the buffer
cooled down. Endogenous peroxidase activity was blocked via
incubation in 3%H2O2 at room temperature for 10min. Blocking
serum was added in a dropwise manner at room temperature
for 20min to reduce the non-specific background. Samples
were incubated with the anti-ALDH1A1 monoclonal antibody
(ab-134188; 1:100 dilution; Abcam, Cambridge, MA, USA)
overnight at 4◦C. Sections were washed in PBS three times
for 2min and then incubated with a biotinylated secondary
antibody (PK-4001; Vector Labs, USA) for 30min at room
temperature. The slides were subsequently incubated with
ABC-HRP (PK-4001; Vector Labs, USA) for another 30min,
washed in PBS, and stained with 3,3-diaminobenzidine. Finally,
the sections were counterstained with Mayer’s hematoxylin,
dehydrated, and mounted. Images were collected using a
Zeiss Axioskop microscope with a Zeiss Axiocam ICc3 High-
Resolution Microscope Camera. The scoring of the ALDH1A1
staining was performed by two independent investigators who
were blinded to the patients’ clinicopathological characteristics.
Sections were scored independently. Immunoreactivity was
scored using a semiquantitative method based on the ALDH
positivity of the tumor cells as follows: 0 (<5% positive), 1 (5–
25% positive), 2 (>25–50% positive), 3 (>50–75% positive), and
4 (>75% positive) (55).
Cell Transformation Assay
Cell Biolabs CytoSelectTM 96-well cell transformation assay (cell
recovery compatible, fluorometric) was used to analyze the
anchorage-independent growth of ALDHhigh cells, and theMCF-
7 cell line was used as a positive control. ALDHhigh cells were
harvested and cultivated for a maximum of 48 h in appropriate
serum-free medium, as described below. MCF-7 cells were
cultivated in DMEM (Gibco) containing 50 IU/ml penicillin–
streptomycin and 4mM glutamine in the presence of 10% FBS
(Euroclone). Cells were used at a concentration of 9,000 cells
per well of the 96-well plate, and the growth kinetics on day 0
(T0) and day 8 (T8) were chosen to measure cell growth. This
kit provided the soft agar material, solubilization solution, lysis
buffer, and Cyquant R© GR Dye. The dye binds nucleic acids, and
the relative fluorescence units (RFUs) were quantified to reveal a
relative quantity of cells based on nucleic content.
MTS Assay
The MTS Cell Proliferation Kit (Abcam) was used to measure
the cell proliferation rate at six different time points after seeding
(0, 1, 2, 7, 14, and 21 days). In a final volume of 200 µl of cell
culture medium, 20 µl of MTS was added and incubated for
4 h at 37◦C in standard culture conditions. After incubation, the
optical density wasmeasured at 490–500 nmby aGlomaxMulti+
Detection System (Promega).
Tumor Sphere-Forming Assay
ALDHhigh and ALDHlow tumor spheres were dissociated into
single-cell suspensions, and 50,000 cells from four different
patients, two ADENO and two SQUAMO, were transferred
to 24 ultralow attachment well plates. Cells were cultured
in a mixture of serum-free DMEM and Ham’s F12 media
(2:1) (Gibco) containing 50 IU/ml penicillin–streptomycin and
4mM glutamine supplemented with 5µg/ml insulin, 10 ng/ml
epidermal growth factor (EGF), 20 ng/ml basic fibroblast growth
factor, 0.18 nM adenine, and 2 nM triiodotironin. The cells were
cultured in 5% CO2 at 37
◦C for 2 weeks, and the media were
replaced or supplemented with fresh growth factors twice a week.
The entire well was digitally photographed using inverted phase-
contrast microscopy (Zeiss Axioskop and Axiocam ICc3 color
camera). All images were analyzed using the AxioVision software
(Zeiss). The total number of spheres was counted, and sphere
areas were manually measured at three different time points: 1,
2, and 3 weeks from seeding (56, 57).
RT-PCR Data Analysis
We included four patients with ADENO and four patients
with SQUAMO in the analysis, for a total of eight patients.
This study uses a three-factor full factorial experimental design
with replications, with factors such as (1) ALDHhigh and
ALDHlow cells; (2) SOX2, NANOG, and GAPDH genes; and (3)
ADENO and SQUAMO histotypes. Replications are represented
by triplicates. The analysis was performed using a linear mixed-
model approach (58), which allows formal statistical hypothesis
testing of relative gene expression. All cycle threshold values≥36
were set as equal to 36. We assessed the relative messenger RNA
(mRNA) expression of SOX2 and NANOG genes, normalized to
the expression of the housekeeping gene, GAPDH, in ALDHhigh
cells compared to ALDHlow cells by means of a linear mixed
regression model. The dependent variable was cycle threshold
(Ct), whereas the independent variables were ALDH (high vs.
low), gene (SOX2 and NANOG vs. GAPDH, which is the
reference category), histotype (ADENO vs. SQUAMO), and
pairwise and three-way interactions, all of which were analyzed
as fixed-effect factors. The model also included a random
intercept and a random ALDH–histotype interaction term that
was specific for each patient to take into account correlations
among cycle threshold values. The following parameters of
interest were examined: (1) relative expression of SOX2 and
NANOG in ALDHhigh cells compared to ALDHlow cells in
adenocarcinoma; (2) relative expression of SOX2 and NANOG
in ALDHhigh cells compared to ALDHlow cells in squamous cell
carcinoma; and (3) differences between ADENO and SQUAMO
in SOX2 and NANOG relative expression in ALDHhigh cells
compared to ALDHlow cells. The relative expression of SOX2
and NANOG in ALDHhigh cells compared to ALDHlow cells,
using GAPDH as the housekeeping gene, is reported as the
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fold change and the difference in cycle thresholds (equal to –
log2 fold change) with 95% confidence intervals and p-values.
Comparisons between ADENO and SQUAMO for SOX2 and
NANOG relative expression in ALDHhigh cells compared to
ALDHlow cells are reported as p-values. All tests were two-sided
t-tests using the Satterthwaite method for degrees of freedom.
Statistical Analysis
Continuous variables were expressed as the mean ± standard
deviation (SD) and the range, and categorical variables were
expressed as absolute and percent frequencies. Statistical analyses
of RT-PCR data were described in the previous paragraph. All
statistical analyses were performed with R 3.4.3 software (The R
Foundation for Statistical Computing, Wien) with p< 0.05 as the
significance level.
Sample Size
No formal sample size estimation was carried out in this
pilot study. Therefore, the number of patients included in the
analyses was only based on resource availability. The enrolled
patients were those who underwent major surgical lung resection
for stage I, II, or IIIA NSCLC in our division over a time
period of 4 months. We included four consecutive patients
with ADENO and four consecutive patients with SQUAMO to
balance the two types of patients according to our full factorial
experimental design.
Genomics
Genomics data were routinely recorded in our Hospital
for ADENO. DNA was extracted from formalin-fixed and
paraffin-embedded blocks of each tumor sample. Extraction
was performed with the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany), and DNA was quantified with Xpose-NGS
(Trinean NV, Gentbrugge, Belgium). Mutations were detected in
genome-amplified DNA using the high-throughput genotyping
platform SequenomMassARRAY System (Sequenom, San Diego,
CA, USA) and the Myriapod Colon Status Kit (Diatech
Pharmacogenetics, Italy) following the manufacturer’s protocol.
This molecular array allows for the identification of the most
important mutations of the KRAS,NRAS, BRAF, EGFR, PIK3CA,
and ERBB2 genes.
RESULTS
Lung Cancer Tissues From Patients Yield
Sufficient Numbers of Living Cells After
Dissociation
All eight patients enrolled in the study (mean age, 71 ± 8.5
years old; range, 61–83; six male, two female, all smokers)
underwent a lobectomy by lateral thoracotomy. Four patients
were diagnosed with adenocarcinoma of the lung (mean age,
66.7 ± 9.4 years old; range, 61–79; three male, one female),
and four patients (mean age, 73.7 ± 7.9 years old; range, 65–
83; three male, one female) were diagnosed with squamous
cell carcinoma (Table 1). Surgical tumor specimens (mean, 1.0
± 0.7 g; range, 0.2–2.2) were obtained from each patient and
used for the experiments, with similar specimen weights in
the ADENO and SQUAMO groups (Table 1). A procedure
combining mechanical dissociation with enzymatic degradation
of the extracellular matrix that maintained tissue structural
integrity was used to obtain single-cell suspensions from the
surgical tumor specimens. The average cellular yield was a mean
of 19.3 ± 7.9 million cells per gram (range, 10.0–30.3), with
similar cellular yields in ADENO and SQUAMO (Table 1). Good
cell viability was further confirmed by FACS analysis.
ALDH-Positive Stem-Like Cells Were
Identified in Primary Lung Cancer Tissue
Tumor tissue dissociation efficiently released cancer cells
characterized by a heterogeneous morphology, as illustrated by
widespread FSC and SSC values (Figure 1A). The mean viability
of the samples was 92.4 ± 6.0% (range, 82.9–99.4%) based on
7-AAD staining (Table 1). These data further confirmed that
the developed dissociation procedure was a non-toxic approach
to isolating cancer cells from tumor tissues (Figure 1). The
putative CSCs were physically separated from the bulk parental
tumor cells and recovered by FACS according to the following
gating strategy: Tumor cells were first identified based on
their morphological parameters (FSC/SSC, Figure 1A, gate P1),
and ALDH activity was measured in the 7-AAD-negative cell
population only (Figure 1B). ALDHlow and ALDHhigh cells were
selected and sorted (Figure 1C). An ALDHhigh subpopulation
was identified in all samples (mean, 4.0 ± 4.6%; range, 0.5–
12.5%, with two samples above 5%) of all viable lung cancer cells
(Table 1), which indicates that it was possible to preserve lung
cancer cells using a rapid dissociation protocol that allowed the
identification of putative CSCs.
Primary Lung Tumor Cells Express CD44
The surface marker CD44 was investigated as a possible marker
for cancer stem-like cells. 7-ADD was used to identify viable
cells, and CD45 staining was used to exclude CD45-positive cells
(Figure 2) (59).
We found that ALDHhigh and CD44-positive cells had
comparable expression in our samples (4.0 ± 4.6 and 11.5 ±
7.7%, respectively), and there was a moderate positive correlation
(Pearson correlation= 0.52).
SOX2 and NANOG in ALDHhigh/low Cells in
Adenocarcinoma and Squamous Cell
Carcinoma
A total of 143 Ct values were available. Two patients (one
ADENO and one SQUAMO) had SOX2 and NANOG Ct values
in triplicate above 36 cycles in ALDHlow cells, and one ADENO
patient had SOX2 and NANOG Ct values in triplicate above
36 cycles in ALDHlow cells and NANOG Ct values in triplicate
above 36 cycles in ALDHhigh cells. A total of 25 (17.5%) Ct
values were above 36 and set equal to 36 for data analysis.
The results from linear mixed-model analysis are reported
in Table 2. The fold changes in ADENO were 20.72 (95%
CI = 0.68; 635.58, p = 0.0755) and 25.49 (95% CI = 2.29;
283.44, p = 0.0147) for SOX2 and NANOG, respectively. The
fold changes in SQUAMO were 0.14 (95% CI = 0.02; 1.13,
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FIGURE 1 | Cells with high aldehyde dehydrogenase (ALDH) activity in one patient sample (1.2%). (A–C) The gating strategy of a representative
fluorescence-activated cell sorting (FACS) analysis of a primary tumor cell suspension in one patient. 7-Amino-actinomycin D (7-AAD) was used to assess
ALDHhighorlow on the live population of cells.
FIGURE 2 | Cell positivity for CD44. (A–D) The gating strategy of a representative cytofluorimetric analysis of a primary tumor cell suspension. 7-Amino-actinomycin D
(7-AAD) was used to exclude the CD45-positive cells in the live population to further analyze tumor cell positivity for CD44.
p = 0.1022) and 0.07 (95% CI = 0.02; 0.31, p = 0.0073) for
SOX2 and NANOG, respectively. These results are reported
in Figure 3 by both the fold change and the cycle threshold
difference scales. The differences in relative expression between
ADENO and SQUAMO were statistically significant (p = 0.0101
and p= 0.0005 for SOX2 and NANOG, respectively).
ALDH Positivity in Digested Samples
Reflects Immunohistochemical Scoring in
NSCLC
To further evaluate the ALDH expression pattern in the
NSCLC samples, ALDH1A1 immunohistochemistry was scored
as previously reported (55). Tissue sections were examined at
10× magnification to characterize the overall staining pattern
and at 20× magnification for a more accurate evaluation of
the cells to assign the appropriate values. As expected, normal
bronchial epithelium and macrophages showed ALDH1A1
expression (49).
All eight patient samples showed a broadly similar intensity of
ALDH1A1 staining in the cancerous fraction (i.e., all had scores
of 0 with <5% positive tumor cells), which is consistent with the
FACS data (Figure 4).
Cell Transformation
The Cell Biolabs CytoSelectTM 96-well cell transformation assay
did not involve subjective manual counting of colonies, but
it used a fluorescent measurement of Cyquant R© GR Dye that
bound to nucleic acids to quantify the number of cells based on
nucleic assay content. We compared the cell proliferation at T0
and T8 between the MCF-7 breast cancer cell line and ALDHhigh
cells. The MCF-7 cell line grew from 130 to 1,233 RFU, and the
ALDHhigh cells rose mildly from 158 to 177 RFU (Figure 5).
MTS Cell Proliferation Assay
Cell proliferation was evaluated in ALDHhigh cells from seeding
(day 0) until the end of the culture (day 21). AnMTS-based assay
revealed that our culture protocol did not affect the proliferation
of ALDHhigh cells. There was a trend of growth that extended
until day 21, without any notable drop in cell growth over
time (Figure 6).
General Characteristics of Tumor Spheres
ALDHhigh cells of the ADENO and SQUAMO patients were
maintained in low attachment cultures in the absence of serum
for up to 3 weeks (Figure 7.1).
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TABLE 2 | SOX2 and NANOG in ALDHhigh/low cells.
1Ct Difference
(95% CI)
FC (95% CI) p-value
SOX2
Adenocarcinoma −4.37
(−9.31; 0.57)
20.72
(0.68; 635.58)
0.0755
Squamous cell
carcinoma
2.79
(−0.17; 5.76)
0.14
(0.02; 1.13)
0.1022
Difference 0.0101
NANOG
Adenocarcinoma −4.67
(−8.15; −1.20)
25.49
(2.29; 283.44)
0.0147
Squamous cell
carcinoma
3.80
(1.71; 5.88)
0.07
(0.02; 0.31)
0.0073
Difference 0.0005
95% CI, 95% confidence interval; FC, fold change. Relative gene expression of SOX2 and
NANOG in ALDHhigh cells compared to ALDHlow cells in adenocarcinoma and squamous
cell carcinoma; results from linear mixed model analysis.
FIGURE 3 | Relative messeger RNA (mRNA) expression of SOX2 and NANOG
in ALDHhigh compared to ALDHlow cell populations, using GAPDH as the
reference gene. Expression was measured for the ALDHlow and ALDHhigh cell
populations in adenocarcinoma and squamous cell carcinoma histotypes
using real-time PCR (RT-PCR), and relative expression comparing ALDHhigh
and ALDHlow was calculated by means of a linear mixed model. The two light
gray bars represent ADENO, and the two dark gray bars represent SQUAMO.
The error bars represent the 95% confidence intervals. ADENO,
adenocarcinoma; SQUAMO, squamous cell carcinoma.
The tumor spheres that formed in each well were counted and
measured for area in ADENO and SQUAMO patients at three
different time points (1, 2, and 3 weeks), as shown in Figure 7.2.
There was a tendency for ADENO to produce a higher number
of spheres than SQUAMO, and the spheres produced by ADENO
also exhibited greater area than SQUAMO. We observed that the
spheres in ADENO had a tendency to grow in area and form
larger spheres at 2 and 3 weeks, but there was no evidence of this
in SQUAMO spheres, whose distribution did not significantly
change over time. In contrast, ALDHlow cells of both histotypes
died within 3 days, as shown in Figure 8.
Genomics
Genomics data were recorded for four ADENO patients. Two of
them had a KRAS mutation, one had an EGFR mutation and one
patient was wild type for the analyzed mutations.
DISCUSSION
The CSC theory elucidates the origin of tumors, tumor
development, metastasis, relapse, and drug resistance (60, 61).
Therefore, the establishment of a reliable and efficient method
for the isolation, manipulation, and characterization of CSCs
is controversial, presumably due to the difficulty of identifying
a specific marker. Thirty years ago, Carney and colleagues
described a rare population of cells (<1.5%) in small and
NSCLC samples that formed colonies in soft agar (62). When
inoculated into athymic nude mice, these cells recapitulated the
original lung cancer, which suggested that they had progenitor
cell features (63). Over the last decade, several investigators
isolated tumorigenic cell lines from lung cancers using different
phenotypic cancer cell characteristics (48).
In the past, different methods have been used to identify CSCs,
such as side population analysis, selection in culture, and cell
sorting for a specific marker (64–67). Of all the markers explored,
the CD133marker has received themost attention (48). However,
in our samples, the CD133 marker was not useful because of a
lack of detection, as described previously (48). Consequently, we
analyzed our population for CD44, which is a transmembrane
receptor for hyaluronic acid that is a CSC marker of several stem
cell-like properties (68). In addition, we used the ALDEFLUOR
assay to isolate cancer stem-like cells, as previously described
by Sullivan et al. (52). Interestingly, our results confirmed
comparable ALDHhigh and CD44 positive expression.
However, Sullivan et al. identified CSCs in a panel of 11
NSCLC tumor samples, 45 NSCLC lines, and 7 SCLC lines (52)
that are used to study ALDH activity and sorted a subpopulation
of NSCLC stem-like cells dependent on Notch signaling. Our
study used the same method (52), but we focused on analyzing
the differences and similarities between adenocarcinoma and
squamous cell carcinoma cancer stem-like cells. Our hypothesis
was supported by the fact that these populations are the
most frequent histotypes in lung cancer patients and account
for 50% of adenocarcinoma patients and 30% of squamous
cell carcinoma.
We investigated the ALDHhigh/low populations in both
histotypes for the mRNA expression of SOX2 and NANOG,
which are stemness-related genes in normal and cancer cells
(60, 61).
The RT-PCR data from our patients revealed more SOX2 and
NANOG expression in ALDHhigh cells than in ALDHlow cells in
adenocarcinoma. However, the opposite result was obtained for
squamous cell carcinoma, in which lower SOX2 and NANOG
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FIGURE 4 | Immunohistochemical staining intensity of aldehyde dehydrogenase. Representative images of two patient samples in squamous cell carcinoma (A) and
adenocarcinoma (B). Images were taken at 10× (upper panels) and 20× (lower panels) magnification; black arrows indicate positive cells.
FIGURE 5 | Cell transformation assay. The MCF-7 cell line and ALDHhigh cells
were compared for growth ability in a semisolid agar substrate. Two different
time points were evaluated: 0 and 8 days. In the vertical axis, DNA content of
each sample was measured using a fluorescent signal released by Cyquant
GR Dye. Time points are represented in the horizontal axis.
expression was found in ALDHhigh cells than in ALDHlow cells.
Therefore, there was a concordant trend for SOX2 and NANOG
relative mRNA expression, even though only the relative
expression of NANOG reached statistical significance. There was
a statistically significant difference between the relative mRNA
FIGURE 6 | Cell proliferation assay. A colorimetric assay,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS) based,
was performed on ALDHhigh cells after seeding. Six different time points were
evaluated (0, 1, 2, 7, 14, and 21 days). Absorbance was measured at 490 nm.
expression of SOX2 and NANOG in adenocarcinoma compared
to squamous cell carcinoma. The expression of these genes was
discussed in previous attempts to find a connection between these
stemness genes and the clinicopathological features of the tumor
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FIGURE 7 | General characteristics over time of tumor spheres in adenocarcinoma and squamous cell carcinoma. (1A–C) ALDHhigh spheres from ADENO at 1, 2, and
3 weeks. (1D–F) ALDHhigh spheres from SQUAMO at 1, 2, and 3 weeks. (2A–F) The number of spheres and their areas were calculated for two adenocarcinoma
patients and two squamous cell carcinoma patients 1, 2, and 3 weeks after seeding. Points represent values for individual patients, and bars represent average
values. ADENO, adenocarcinoma; SQUAMO, squamous cell carcinoma.
FIGURE 8 | ALDHlow cells phase-contrast microscopy. ALDHlow cells in low-attachment serum-free culture showed difficult and slow growth that completely stopped
at 3 days.
(68–70). Therefore, our study adds a new aspect by considering
the existence of different cancer-stem-like cell populations
for these two histotypes. However, our data suggest an
enrichment of cells with stemness characteristics.
To further confirm CSC-like phenotypes, we analyzed the
ability of cells to form tumor spheres in serum-free low-
attachment cultures. Tumor sphere formation assays revealed a
different pattern in sphere formation, dimension, and growth
between adenocarcinoma and squamous cell carcinoma. The
former had a tendency to produce a greater number of spheres
and larger spheres than the latter. Moreover, we observed growth
of adenocarcinoma spheres until the third week, but spheres
from the squamous cell carcinoma did not increase in number or
size. This result may be related to the distinct aggressiveness and
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clinicopathological characteristics of adenocarcinoma compared
to squamous cell carcinoma.
Furthermore, genomics data highlighted the presence of
genetic mutations in ADENO; however, the relationship of
these mutations with the cancer stem-like cells in our study
is unclear.
LIMITATIONS OF THE STUDY
The main limitation of the study is the low number of patients
included in the analyses (four ADENO and four SQUAMO).
The selection of these few patients could have affected our
results as well as the statistical power. Nevertheless, we have
included consecutive patients—which prevents from selection
bias—and we have observed statistically significant differences in
gene expression between ADENO and SQUAMO, which partially
counterbalances the issue regarding the low statistical power.
Moreover, in this study, test samples were obtained by primary
cell cultures derived from patients, which is more difficult to
obtain than tumor cell lines. On the basis of these limitations, the
results obtained in our pilot study should be confirmed by more
extensive studies.
CONCLUSION
Even with limited evidence due to the low number of patient
samples, our study showed differences between adenocarcinoma
and squamous cell carcinoma related to the analyzed stemness
genes. ALDHhigh cancer stem-like cells in adenocarcinoma
showed stemness characteristics in gene expression and
spheroid culture studies, but squamous cell carcinoma stemness
characteristics were not completely clear because of the
discrepancy between genes and cellular behavior.
To summarize, our results highlight the importance of a
better characterization of cancer stem-like cells in ADENO
and SQUAMO histotypes. This may suggest new differential
approaches for prognostic and therapeutic purposes in patients
with NSCLC.
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